Vashisht Gopal Yennu Nanda, Ph.D. Photo courtesy of The University of Texas MD Anderson Cancer Center Researchers at The University of Texas MD Anderson Cancer Center report that tailoring targeted drug combinations to tumour dependence on BCL2 family proteins may restore treatment responses in patients with advanced melanoma that has progressed on standard BRAF-MEK therapy. These personalized strategies may improve outcomes in this challenging patient population and, in addi